ECCO 2026: Long-Term Efficacy and Safety of Mirikizumab in Crohn’s Disease

Edward L. Barnes, MD, MPH, Associate Professor of Medicine and Director of the Gastroenterology & Hepatology Fellowship at the University of North Carolina, USA, presented long-term data from the VIVID-2 open-label extension study evaluating mirikizumab in Crohn’s disease at ECCO 2026. The analysis demonstrated sustained endoscopic and clinical efficacy through 104 weeks, alongside a consistent safety profile without new safety signals. The study also highlighted the potential benefit of re-induction therapy in patients without initial endoscopic response, supporting mirikizumab as a durable long-term treatment strategy in Crohn’s disease.